ClinicalTrials.gg
RecruitingNCT05704348Updated Oct 30, 2024

Sleeve-pex: A Randomized Trial to Reduce Reflux After Sleeve Gastrectomy

An interventional study of Sleeve gastrectomy with gastropexy and Sleeve gastrectomy without gastropexy in Gastroesophageal Reflux, sponsored by Helse Forde. Recruiting at 4 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Helse Forde · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Gastroesophageal Reflux with a site in Norway — 3 open to participants now, 4 under way, none of them phase 3. Gastroesophageal Reflux · Norway.

Planned enrollment
5th of 12
550 · median 297
Started
2023
with 1 other
No phase
4 of 15
2 open now
Registered
14th of 15
by date
Lead sponsor
1 of 15
Helse Forde

Among the 15 studies in Gastroesophageal Reflux with a site in Norway, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 4 with no phase, and was the 14th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

3 of the 15 studies in Gastroesophageal Reflux with a site in Norway are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Gastroesophageal Reflux with a site in Norway, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test gastropexy as a measure to reduce reflux in morbidly obese patients being submitted to sleeve gastrectomy. The main questions it aims to answer are:

Does gastropexy reduce reflux symptoms? Does gastropexy reduce objective evidence of reflux? Participants will be randomized to gastropexy or no gastropexy, and researchers will compare these groups to see if reflux (symptoms / objective evidence of) is different in the two groups.

Read the detailed description

Laparoscopic sleeve gastrectomy (LSG) has become the most commonly performed bariatric procedure worldwide. LSG consists of a longitudinal resection of the stomach leaving the intestines intact, thereby lowering the risk for side-effects due to rerouting of the small bowel. However, gastro-esopageal reflux disease (GERD) has been reported to increase after LSG. Our hypothesis is that GERD is mainly due to intrathoracic migration of the gastric remnant. The aim of this study is to explore if suturing the gastric remnant to the gastrocolic ligament (gastropexy) will prevent intrathoracic migration and thereby reduce the development of reflux.

Patients planned for a sleeve gastrectomy will be invited to participate, and participating patients will be randomized to pexi or no pexi. According to power calculations a total of 550 patients will be randomized in the study. Follow-up will be at six weeks, one-, two- and five years.

03

Conditions studied

  • Gastroesophageal Reflux
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients planned for bariatric surgery with primary LSG

Exclusion criteria

Exclusion Criteria:

  • Age below 18 yrs
  • Use of ARM for other reasons than reflux
  • Previous antireflux surgery
  • Inability to comprehend and respon to patient related outcome (PRO) questionnaire
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
550 participants (estimated)

Study arms

  • Active comparator
    No gastropexy

    Sleeve gastrectomy without gastropexy.

    Procedure: Sleeve gastrectomy without gastropexy

  • Experimental
    Gastropexy

    Sleeve gastrectomy with gastropexy

    Procedure: Sleeve gastrectomy with gastropexy

Interventions

  • ProcedureSleeve gastrectomy with gastropexy

    Gastropexy in this project means suturing the gastric remnant to the gastrocolic ligament.

  • ProcedureSleeve gastrectomy without gastropexy

    Sleeve gastrectomy without suturing the gastric remnant to the gastrocolic ligament.

06

What researchers measure

Primary outcomes

  1. Number of participants using acid-reducing medication (ARM) or having had reoperations due to GERD

    ARM: Daily use of ARM for the last month

    Time frame: Two years

Secondary outcomes

  1. Endoscopic findings

    Visible oesophagitis according to the LA classification

    Time frame: Two years

  2. Patient related outcome

    GerdQ questionnaire

    Time frame: Two years

  3. pH-metry

    pH measurement by Bravo capsule

    Time frame: Two years

07

Study locations

3 of 4 sites recruiting
  • Helse Forde
    Førde, Norway
    Not yet recruiting
  • Aleris Oslo
    Oslo, Norway
    Recruiting
    • Bent Johnny Nergård, MD · Contact
  • Volda sjukehus
    Volda, Norway
    Recruiting
    • Therese Saunes, MD · Contact
  • Voss sjukehus
    Voss, Norway
    Recruiting
    • Jonas Nedkvitne, MD · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Information about Sleeve-pex will be found at the SOReg-N webpage.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: The study protocol including analysis plan and formula for informed consent will be available at the SOReg-N webpage from the beginning of the study.

Access criteria: The study protocol is available at SOReg-N webpage. Data from the study will be made available for other researchers on request if approved by the ethical review board.

Data sharing details ↗ · helse-bergen.no

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2027, 51 months after the start.

Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 51 months is above that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Jan 30, 2023
StartActual
Sep 4, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2030
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05704348
Lead sponsor
Helse Forde
Responsible party
Villy Våge (Project leader, Helse Forde) — Principal investigator
First posted
Jan 30, 2023
Start date
Sep 4, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 30, 2024

Study contacts

Villy Vage, MD PhD
Contact
villy.vage@helse-bergen.no
47 90863744
John Andersen, PhD
Contact
john.roger.andersen@helse-forde.no
47 48278186
Villy Vage, MD PhD
study chair · Helse Forde

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion